Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa E Davis

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
The American Journal of Managed Care|September 13, 2018
The evolution of biomarkers to guide the treatment of metastatic colorectal cancerLisa E Davis
Clinical Therapeutics|December 25, 2003
Zoledronic acid: a new parenteral bisphosphonateEdward C Li, Lisa E Davis
The Annals of Pharmacotherapy|May 2, 2023
Fixed Versus Body-Sized-Based Dosing of Monoclonal AntibodiesBrian L Erstad, Lisa E Davis
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 1, 2021
The relationship of vancomycin 24-hour AUC and trough concentrationDavid E Nix, Lisa E Davis, Kathryn R Matthias
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 5, 2022
Response to Rybak et alDavid E Nix, Lisa E Davis, Kathryn R Matthias
American Journal of Pharmaceutical Education|February 12, 2025
Fixed, Systematically Formed versus Continuously Changing Random Team Assignments and Outcomes in a Therapeutics CourseAshley M Campbell, Prince Bosiako Antwi, Lisa E Davis, et al.
Cancer Immunology Research|August 7, 2019
PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath TumorLisa E Davis, Lauren A Nicholls, Hani M Babiker, et al.
Clinical Breast Cancer|April 3, 2020
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast CancerLea E Mollon, Elizabeth J Anderson, Joni L Dean, et al.
International Journal of Breast Cancer|July 9, 2020
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast CancerElizabeth J Anderson, Lea E Mollon, Joni L Dean, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2012
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiencyQuentin McAfee, Zhihui Zhang, Arabinda Samanta, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
The American Journal of Managed Care|September 13, 2018
The evolution of biomarkers to guide the treatment of metastatic colorectal cancerLisa E Davis
Clinical Therapeutics|December 25, 2003
Zoledronic acid: a new parenteral bisphosphonateEdward C Li, Lisa E Davis
The Annals of Pharmacotherapy|May 2, 2023
Fixed Versus Body-Sized-Based Dosing of Monoclonal AntibodiesBrian L Erstad, Lisa E Davis
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 1, 2021
The relationship of vancomycin 24-hour AUC and trough concentrationDavid E Nix, Lisa E Davis, Kathryn R Matthias
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 5, 2022
Response to Rybak et alDavid E Nix, Lisa E Davis, Kathryn R Matthias
American Journal of Pharmaceutical Education|February 12, 2025
Fixed, Systematically Formed versus Continuously Changing Random Team Assignments and Outcomes in a Therapeutics CourseAshley M Campbell, Prince Bosiako Antwi, Lisa E Davis, et al.
Cancer Immunology Research|August 7, 2019
PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath TumorLisa E Davis, Lauren A Nicholls, Hani M Babiker, et al.
Clinical Breast Cancer|April 3, 2020
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast CancerLea E Mollon, Elizabeth J Anderson, Joni L Dean, et al.
International Journal of Breast Cancer|July 9, 2020
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast CancerElizabeth J Anderson, Lea E Mollon, Joni L Dean, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2012
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiencyQuentin McAfee, Zhihui Zhang, Arabinda Samanta, et al.
Pageof 2